APRE – aprea therapeutics, inc. (US:AMEX)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

APRE

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

2/5

10:24 pm

apre

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics [Yahoo! Finance]

Medium Report

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics [Yahoo! Finance]

Report

2/5

08:00 am

apre

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

High Report

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Report

1/15

11:12 am

apre

Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Low Report

Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Report

12/17

08:14 am

apre

Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Medium Report

Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Report

12/11

08:33 am

apre

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward [Yahoo! Finance]

Low Report

Report

12/11

08:30 am

apre

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Medium Report

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.